{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:17:48Z","timestamp":1793755068554,"version":"4.6.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Evidence for efficacy of single, high-dose liposomal amphotericin B (LAmB) in HIV-associated cryptococcal meningitis and histoplasmosis is growing. No systematic review has examined the safety of this regimen across multiple studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We systematically searched Medline, Scopus, and the Cochrane Library from inception to April 2023 for studies reporting grade 3 and 4 adverse events (AEs) with single high-dose LAmB vs traditional amphotericin regimens for HIV-associated fungal infections.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Three trials (n = 946) were included. Compared with traditional regimens, single high-dose LAmB was associated with equivalent risk of grade 3 and 4 AEs (risk ratio [RR], 0.75; 95% CI, 0.53\u20131.06) and lower overall risk of grade 4 AEs (RR, 0.68; 95% CI, 0.55\u20130.86), grade 4 renal (RR, 0.43; 95% CI, 0.20\u20130.94) and grade 4 hematological AEs (RR, 0.46; 95% CI, 0.32\u20130.65).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Single, high-dose LAmB is associated with a lower risk of life-threatening AEs compared with other World Health Organization\u2013endorsed amphotericin B\u2013based regimens in invasive HIV\u2013related fungal infection.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofad472","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T05:47:21Z","timestamp":1695188841000},"source":"Crossref","is-referenced-by-count":8,"title":["Safety of Single High-Dose Liposomal Amphotericin B for Induction Treatment of Cryptococcal Meningitis and Histoplasmosis in People With HIV: A Systematic Review and Meta-analysis"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9794-9666","authenticated-orcid":false,"given":"HeeEun","family":"Kang","sequence":"first","affiliation":[{"name":"Infectious Disease and International Health, Department of Medicine, Dartmouth Hitchcock Medical Center , Lebanon, New Hampshire , USA"},{"name":"Geisel School of Medicine at Dartmouth , Hanover, New Hampshire , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Uy","sequence":"additional","affiliation":[{"name":"Infectious Disease and International Health, Department of Medicine, Dartmouth Hitchcock Medical Center , Lebanon, New Hampshire , USA"},{"name":"Geisel School of Medicine at Dartmouth , Hanover, New Hampshire , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline C","family":"Ho","sequence":"additional","affiliation":[{"name":"Infectious Disease and International Health, Department of Medicine, Dartmouth Hitchcock Medical Center , Lebanon, New Hampshire , USA"},{"name":"Geisel School of Medicine at Dartmouth , Hanover, New Hampshire , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather B","family":"Blunt","sequence":"additional","affiliation":[{"name":"Geisel School of Medicine at Dartmouth , Hanover, New Hampshire , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie B","family":"Riblet","sequence":"additional","affiliation":[{"name":"Geisel School of Medicine at Dartmouth , Hanover, New Hampshire , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro C","family":"Pasqualotto","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Universidade Federal de Ci\u00eancias da Sa\u00fade de Porto Alegre , Porto Alegre , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Murphy","sequence":"additional","affiliation":[{"name":"Infectious Disease and International Health, Department of Medicine, Dartmouth Hitchcock Medical Center , Lebanon, New Hampshire , USA"},{"name":"Geisel School of Medicine at Dartmouth , Hanover, New Hampshire , USA"},{"name":"White River Junction VA Medical Center , Hartford, Vermont , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"key":"2023100510060024700_ofad472-B1","article-title":"Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV"},{"key":"2023100510060024700_ofad472-B2","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa2111904","article-title":"Single-dose liposomal amphotericin B treatment for cryptococcal meningitis","volume":"386","author":"Jarvis","year":"2022","journal-title":"N Engl J Med"},{"key":"2023100510060024700_ofad472-B3","doi-asserted-by":"publisher","first-page":"ciad313","DOI":"10.1093\/cid\/ciad313","article-title":"Single high-dose of liposomal amphotericin B in HIV\/AIDS-related disseminated histoplasmosis: a randomized trial","author":"Pasqualotto","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023100510060024700_ofad472-B4","article-title":"Drug approval package: ambisome (Amphotericin B) NDA# 050740"},{"key":"2023100510060024700_ofad472-B5","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1093\/cid\/ciz076","article-title":"Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin B","volume":"68","author":"Groll","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023100510060024700_ofad472-B6","article-title":"Liposomal amphotericin B: solving the access puzzle","year":"2021"},{"key":"2023100510060024700_ofad472-B7","doi-asserted-by":"crossref","first-page":"e1845","DOI":"10.1016\/S2214-109X(22)00450-8","article-title":"Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in Sub-Saharan Africa: an economic analysis of the AMBITION-cm trial","volume":"10","author":"Lawrence","year":"2022","journal-title":"Lancet Glob Health"},{"key":"2023100510060024700_ofad472-B8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1086\/653606","article-title":"Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety","volume":"51","author":"Hamill","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2023100510060024700_ofad472-B9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2023100510060024700_ofad472-B10","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2023100510060024700_ofad472-B11","year":"2020"},{"key":"2023100510060024700_ofad472-B12","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 6.3 (Updated February 2022)","author":"Higgins","year":"2022"},{"key":"2023100510060024700_ofad472-B13","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 6.3 (Updated February 2022)","author":"Deeks","year":"2022"},{"key":"2023100510060024700_ofad472-B14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"2023100510060024700_ofad472-B15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/ciy515","article-title":"Short-course high-dose liposomal amphotericin B for human immunodeficiency virus-associated cryptococcal meningitis: a phase 2 randomized controlled trial","volume":"68","author":"Jarvis","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023100510060024700_ofad472-B16","doi-asserted-by":"crossref","first-page":"e0004865","DOI":"10.1371\/journal.pntd.0004865","article-title":"Prevalence and hospital management of amphotericin B deoxycholate-related toxicities during treatment of HIV-associated cryptococcal meningitis in South Africa","volume":"10","author":"Meiring","journal-title":"PLoS Negl Trop Dis"},{"key":"2023100510060024700_ofad472-B17","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/cid\/ciac792","article-title":"How applicable is the single-dose AMBITION regimen for human immunodeficiency virus-associated cryptococcal meningitis to high-income settings?","volume":"76","author":"Harrison","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023100510060024700_ofad472-B18","article-title":"Cryptococcosis","author":"National Institutes of Health","year":"2021"},{"key":"2023100510060024700_ofad472-B19","article-title":"Histoplasmosis","author":"National Institutes of Health","year":"2019"},{"key":"2023100510060024700_ofad472-B20","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: a comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"2023100510060024700_ofad472-B21","doi-asserted-by":"crossref","first-page":"a019653","DOI":"10.1101\/cshperspect.a019653","article-title":"Antifungal pharmacokinetics and pharmacodynamics","volume":"5","author":"Lepak","year":"2015","journal-title":"Cold Spring Harb Perspect Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad472\/51698514\/ofad472.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/10\/ofad472\/51882415\/ofad472.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/10\/ofad472\/51882415\/ofad472.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T10:06:29Z","timestamp":1696500389000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad472\/7277557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,20]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad472","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,9,20]]},"article-number":"ofad472"}}